Cubist issued a voluntary recall of four lots of vials due to the presence of particulate matter.
Cubist Pharmaceuticals announced that it is voluntarily recalling four lots of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots, Cubist announced in a press release.
The lots of 500-mg Cubicin in 10-mL, single-use vials were shipped between May 2011 and March 2013. An internal investigation has preliminarily identified the root cause as a manufacturing issue with a supplier, and Cubist has suspended all manufacturing with the supplier until corrective and preventative measures have been taken.
Cubist is notifying customers by letter and phone and notes that existing inventory should be checked. Cubist is arranging for return of recalled product. Glass particulate in an intravenous drug poses a potential safety risk to patients, but no adverse events related to the recall have been reported to date.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.